Fennec Pharmaceuticals (TSX:FRX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.02) by 150 percent. This is a 125 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $15.108 million which beat the analyst consensus estimate of $13.954 million by 8.27 percent. This is a 72.64 percent increase over sales of $8.751 million the same period last year.